Accord Farmacutica Ltda. Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: Accord Farmacutica Ltda. Pharmaceutical Import Records from India — 5 Products, $3.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Farmacutica Ltda. — Pharmaceutical Importer Profile (2026) | 5 Products, $3.3M Trade | TransData Nexus

Accord Farmacutica Ltda.

Pharmaceutical Importer · Brazil · Oncology Focus · $3.3M Total Trade · DGFT Verified

Accord Farmacutica Ltda. is a pharmaceutical importer based in Brazil with a total trade value of $3.3M across 5 products in 3 therapeutic categories. Based on 88 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Accord Farmacutica Ltda. sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Accord Farmacutica Ltda. — Import Portfolio & Supplier Network

Accord Farmacutica Ltda. import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Farmacutica Ltda.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$7.3M	384	100.0%

Accord Farmacutica Ltda. sources from 1 verified Indian supplier across 103 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Accord Farmacutica Ltda. Import?

Formulation	Value	Ships
Pharma drugs & medi metoprolol xr 50MG	$720.7K	22
Pharma drugs & medi paclitaxel INJ USP	$620.2K	18
Pharma drugs & medi metoprolol xr 25MG	$585.1K	28
Pharma drugs & medi bicalutamide 50 MG tabs USP pp 2x15t(e9) as per	$368.6K	12
Pharma drugs & medi metoprolol xr 100MG	$286.0K	9
Pharma drugs and medi mycophenolic	$252.0K	7
Pharma drugs and medi mycophenolate	$250.6K	6
Pharma drugs & medi ivevi letrozol 2.5MG	$191.9K	5
Pharma drugs & medi cytarabine INJ BP 1000MG/10 ML vial as per	$182.9K	4
Pharma drugs & medi paclitaxel INJ USP 6MG/ML, 16.7ML vial as per	$181.0K	6
Pharma drugs & medi clopidogrel	$166.4K	5
Pharma drugs & medi paricalcitol5mcg/ml1ml1x5a(acc-bra)-tend as per	$136.8K	3
Pharma drugs & medi risperidone	$134.2K	10
Pharma drugs & medi cisplatin INJ BP 1MG	$129.0K	12
Pharma drugs & medi irinotecan	$110.5K	4

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Paclitaxel	Oncology	$1.1M	29	1.4%	10
2	Mycophenolate	Immunosuppressants	$950.0K	19	0.3%	14
3	Cytarabine	Advanced Oncology	$794.7K	22	4.3%	2
4	Topotecan	Advanced Oncology	$300.0K	6	5.3%	3
5	Cisplatin	Oncology	$129.0K	12	1.0%	16

Accord Farmacutica Ltda. imports 5 pharmaceutical products across 3 categories into Brazil totaling $3.3M.

Accord Farmacutica Ltda. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Farmacêutica Ltda. is a Brazilian pharmaceutical importer and wholesaler specializing in the distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in São Paulo, Brazil, the company operates under the CNPJ number 64.171.697/0001-46. Its primary focus is on sourcing and distributing oncology, hematology, and critical care medications, aligning with the therapeutic areas of its parent company, Intas Pharmaceuticals Limited. (econodata.com.br)

As a key player in Brazil's pharmaceutical supply chain, Accord Farmacêutica Ltda. serves as a critical link between international manufacturers and the Brazilian healthcare system. By importing and distributing a diverse range of pharmaceutical products, the company ensures the availability of essential medications across the country, contributing to the overall health infrastructure. Its strategic partnerships and efficient distribution network enable it to meet the growing demand for specialized treatments in Brazil.

2Distribution Network

Accord Farmacêutica Ltda. maintains a centralized distribution model from its São Paulo headquarters, facilitating efficient logistics and inventory management. While specific warehouse locations are not publicly disclosed, the company's strategic position in São Paulo allows for effective distribution throughout Brazil. This centralization enables timely delivery of pharmaceutical products to various regions, ensuring consistent supply to healthcare providers nationwide.

The company's logistics capabilities are enhanced by its affiliation with Intas Pharmaceuticals Limited, which operates multiple certified manufacturing facilities globally. This affiliation ensures a steady supply of high-quality pharmaceutical products, leveraging Intas's established distribution channels and expertise in international logistics. Accord Farmacêutica Ltda.'s distribution network is designed to meet the diverse needs of the Brazilian market, ensuring that critical medications reach healthcare facilities and patients promptly.

3Industry Role

Accord Farmacêutica Ltda. functions primarily as a pharmaceutical importer and wholesaler within Brazil's healthcare sector. By sourcing finished pharmaceutical formulations from international manufacturers, particularly from India, the company plays a pivotal role in introducing and distributing a wide array of medications to the Brazilian market. This includes treatments in oncology, hematology, and critical care, addressing the specific therapeutic needs of the Brazilian population.

In addition to its importing and wholesaling activities, Accord Farmacêutica Ltda. collaborates with various stakeholders in the healthcare system, including hospitals, clinics, and government agencies. These collaborations ensure that essential medications are accessible to patients across Brazil, thereby contributing to the overall improvement of public health. The company's strategic partnerships and efficient distribution channels underscore its significant position in the pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Farmacutica Ltda.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Farmacêutica Ltda. exhibits a high degree of sourcing concentration, with all its pharmaceutical imports originating from a single supplier: Intas Pharmaceuticals Limited. This exclusive sourcing strategy has resulted in a total import value of $3.3 million USD over 88 shipments, encompassing 103 unique formulations across five products in three therapeutic categories. The top five imported products include Paclitaxel ($1.1 million, 1.4% share), Mycophenolate ($950K, 0.3% share), Cytarabine ($795K, 4.3% share), Topotecan ($300K, 5.3% share), and Cisplatin ($129K, 1.0% share).

This single-source dependency presents both strategic advantages and potential risks. On the positive side, a focused relationship with Intas Pharmaceuticals Limited may lead to favorable pricing, consistent product quality, and streamlined logistics. However, the lack of supplier diversification could expose Accord Farmacêutica Ltda. to supply chain disruptions in the event of issues such as production delays, regulatory challenges, or geopolitical tensions affecting the supplier. The company's reliance on a single supplier underscores the importance of maintaining a robust and resilient supply chain to mitigate potential risks.

2Supply Chain Resilience

Accord Farmacêutica Ltda.'s supply chain resilience is closely tied to its exclusive partnership with Intas Pharmaceuticals Limited. This relationship ensures access to a diverse portfolio of 103 unique pharmaceutical formulations, encompassing five products across three therapeutic categories: Oncology (38.2%), Advanced Oncology (33.1%), and Immunosuppressants (28.7%). The comprehensive range of products indicates a well-established and reliable supply chain.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the primary regulatory authority overseeing pharmaceutical imports is the National Health Surveillance Agency (ANVISA). ANVISA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Brazilian market. The agency establishes and enforces regulations governing the importation, registration, and commercialization of pharmaceutical products.

Key legislation governing pharmaceutical imports includes the Brazilian Health Regulatory Agency Law (Law No. 9,782/1999) and the Health Surveillance System Law (Law No. 13,410/2016). These laws outline the procedures for product registration, import licensing, and compliance with Good Manufacturing Practices (GMP). For Indian generics to be marketed in Brazil, they must undergo a registration process with ANVISA, demonstrating compliance with Brazilian standards and regulations.

2Import Licensing & GMP

Import licensing in Brazil requires that pharmaceutical products be registered with ANVISA before they can be imported and marketed. This process involves submitting comprehensive documentation, including evidence of GMP compliance, product specifications, and clinical data. ANVISA recognizes GMP certifications from reputable international bodies, such as the European Medicines Agency (EMA), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian manufacturers seeking to export generics to Brazil must ensure their facilities hold valid GMP certifications from these recognized organizations.

Accord Farmacutica Ltda. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Farmacêutica Ltda.'s focus on importing products in the oncology, hematology, and critical care therapeutic areas aligns with the growing demand for specialized treatments in Brazil. The Brazilian healthcare system faces challenges in providing access to advanced therapies, making these areas critical for patient care. By sourcing medications in these categories, Accord Farmacêutica Ltda. addresses unmet medical needs and contributes to improving health outcomes.

The market demand for these imports is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical research leading to new treatment options. Accord Farmacêutica Ltda.'s strategic product selection positions it to meet these evolving healthcare needs effectively.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Accord Farmacutica Ltda.

What products does Accord Farmacutica Ltda. import from India?

Accord Farmacutica Ltda. imports 5 pharmaceutical products across 3 categories. Top imports: Paclitaxel ($1.1M), Mycophenolate ($950.0K), Cytarabine ($794.7K), Topotecan ($300.0K), Cisplatin ($129.0K).

Who supplies pharmaceuticals to Accord Farmacutica Ltda. from India?

Accord Farmacutica Ltda. sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $7.3M).

What is Accord Farmacutica Ltda.'s total pharmaceutical import value?

Accord Farmacutica Ltda.'s total pharmaceutical import value from India is $3.3M, based on 88 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Farmacutica Ltda. focus on?

Accord Farmacutica Ltda. imports across 3 categories. The largest: Oncology (38.2%), Advanced Oncology (33.1%), Immunosuppressants (28.7%).

Get Full Accord Farmacutica Ltda. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.